AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 1 mg
Description: A single dose of CC-220 1 mg will be administered orally once a day.
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220 2 mg
Description: A single dose of CC-220 2 mg will be administered orally once a day.
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A single dose of placebo will be administered orally once a day.
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 4 mg will be administered orally once a day
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 6 mg will be administered orally once a day
Study NCT01733875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-220
Description: CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
Study NCT01263964 — intervention group
Intervention type: PROCEDURE
Intervention: coronary angiogram
Description: coronary angiogram
Study NCT03378817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HOPE
Description: HOPE for 1 hour via the renal artery in a recirculating and pressure controlled system, Belzer (UW) machine perfusion solution, perfusate temperature 0-4 °C, perfusate oxygenation pO2 of 60-80 kPa Other Name: Hypothermic machine perfusion (HMP)
Study NCT03378817 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold storage
Description: No intervention
Study NCT01784731 — intervention group
Intervention type: BEHAVIORAL
Intervention: Willingness to pay
Study NCT02736058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans- abdominal sonography
Study NCT02736058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-vaginal sonography
Study NCT02736058 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-operative pathological specimen examination
Study NCT01332123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alignment perturbations
Description: Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
Study NCT00796666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
Study NCT00796666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan and Sildenafil
Description: Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
Study NCT00800566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Clofarabine
Description: The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
Study NCT02171507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran etexilate
Study NCT02171507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study NCT02171507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT02171507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Study NCT02653326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Monitors
Description: After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
Study NCT02653326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
Study NCT02653326 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
Study NCT02653326 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counseling
Description: Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
Study NCT02653326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Counseling
Description: Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
Study NCT02653326 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depression Screening
Description: Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
Study NCT02653326 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression Screening
Description: Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
Study NCT02653326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment of Comorbidities
Description: Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
Study NCT02653326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment of Comorbidities
Description: Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
Study NCT01028105 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative MRSA screening
Description: MRSA preoperative screening and post operative infection rate, 30 days post operative
Study NCT03041571 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Provider Orientation Scale
Description: Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
Study NCT03041571 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview performed by MHP student
Description: The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system.
Study NCT02255916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: live sound-bed music intervention
Study NCT00802516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: stanol ester
Description: enriched margarine
Study NCT00802516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: sterol ester
Description: enriched margarine
Study NCT00802516 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: placebo margarine
Study NCT02386046 — intervention group
Intervention type: OTHER
Intervention: Pulse oxymeter measurements
Description: Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
Study NCT00902681 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
Study NCT02374164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat XR capsules
Study NCT00255190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
Study NCT00255190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR
Description: Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
Study NCT03074708 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D visualization and 3D printing
Description: From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
Study NCT03008161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPT088
Description: IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
Study NCT03008161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02638766 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: regorafenib
Description: Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
Study NCT01811888 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quantitative sensory testing (QST)
Study NCT02767271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luliconazole Cream 1%
Description: Luliconazole cream will be applied topically per schedule specified in the arms.
Study NCT02626585 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postrhinoplasty taping
Description: Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
Study NCT00429559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hycamptin
Description: 1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
Study NCT00429559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.~Number of cycles: until progression
Study NCT02053012 — intervention group
Intervention type: DEVICE
Intervention: PVT-192
Description: PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
Study NCT00657046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: Capsules containing 200 mg droxidopa
Study NCT00657046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Capsules with mannitol substituted for droxidopa
Study NCT00657046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules with mannitol substituted for droxidopa
Study NCT02931019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intubation
Study NCT01303939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: magnetic resonance imaging (MRI) of the brain
Description: High resolution three-dimensional T1-weighted magnetic resonance imaging (MRI) was obtained from each participant at one visit.
Study NCT04197349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD1910
Description: Single Dose IV infusion
Study NCT02830360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrythmic Drug Therapy
Description: Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
Study NCT02830360 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
Study NCT04197349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Description: Single dose subcutaneous injection
Study NCT04197349 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD1910
Description: Single dose subcutaneous injection
Study NCT00286442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and metformin
Description: Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
Study NCT00286442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and metformin
Description: Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
Study NCT00286442 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
Study NCT00961155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyklezonid
Description: 160 mcg once daily
Study NCT00961155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast sodium
Description: 5 or 10 mg according to age once daily
Study NCT00961155 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: fluticasone placebo twice daily, montelukast placebo once daily
Study NCT00961155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol 12 mcg twice daily
Description: formoterol 12 mcg twice daily will be given to children for 3 months
Study NCT02982395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoxel®M
Description: Intravesical
Study NCT02982395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C
Description: Intravesical
Study NCT00670839 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GenHevac-B
Description: 1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
Study NCT00670839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GenHevac-B
Description: 2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
Study NCT02265627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIL 284 BS
Study NCT04019223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: anti-tissue transglutaminase group
Description: Determination of anti-tissue transglutaminase IgA antibodies serum level.
Study NCT04019223 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: biopsy group
Description: Intestinal biopsy for histopathology study the jejunal histopathological
Study NCT02961543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.
Study NCT02961543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic eccentric exercises
Description: The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.~45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours.
Study NCT01488877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: 3 mg tablet once daily
Study NCT01488877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: up to 10 mg tablet once daily
Study NCT01488877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845
Description: up to 30 mg once daily
Study NCT01488877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: spironolactone 25 mg once daily
Study NCT01488877 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily
Study NCT00377442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: 100mg po
Study NCT00377442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 80mg po
Study NCT00752947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin
Description: Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
Study NCT00752947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levofloxacin
Description: Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
Study NCT00752947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metronidazole
Description: metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
Study NCT00955253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 2mg oral guanfacine (encapsulated)
Study NCT00955253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study NCT02197403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion
Study NCT02197403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1\~1.0mcg/Kg infusion
Study NCT02197403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 25\~75mcg/kg/min continuous infusion
Study NCT01567904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semuloparin sodium
Description: Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)~Subcutaneous injection
Study NCT04096053 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEACHH
Description: See arm/group description.
Study NCT00217308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacilli GR-1 and RC-14
Description: Probiotic Lactobacilli will be compared to placebo
Study NCT00217308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacilli GR-1 and RC-14
Description: Probiotic Lactobacilli will be compared to placebo
Study NCT02486276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02486276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02486276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT02486276 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Study NCT04391634 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: volume guarantee
Description: volume guarantee assist-control mechanical ventilation